All News

The real-world data support the long-term value of mepolizumab as an add-on maintenance therapy in severe asthma.

Panels held throughout the conference emphasized both how far the specialization has come but also how far it has yet to go.

New data reinforce elinzanetant’s safety, efficacy, and ability to improve sleep disturbances in menopausal women, independent of vasomotor symptom relief.

Early and lifelong trauma can intensify menopause symptoms and accelerate cardiovascular and brain aging, according to research.

CD45 + C1q + CCR8+ cells were found to be a novel immune-cell subset associated with kidney disease severity and progression risk.

Serum biochemical fingerprints can stratify chronic lymphocytic leukemia (CLL) outcomes and uncover heterogeneity within molecularly defined low-risk disease.

Chronic spontaneous urticaria (CSU) and atopic disorders seem to share an immunological basis and may significantly benefit from type 2 inflammation–targeted therapies.

Treatment options for patients with small cell lung cancer (SCLC) who survive to a third line of therapy are insufficient, authors of a new study argue.

The AMCP Nexus 2025 conference will bring together professionals to discuss drug access and policy, as well as the future of pharmacy.

Glucagon-like peptide 1 receptor agonists improved disease activity, body weight, and cholesterol in patients with rheumatoid arthritis.

Tumor-first multigene testing boosts diagnostic accuracy, minimizes duplication, and aligns with professional society recommendations for integrated sequencing.

Artificial intelligence models may advance clinical trial design and enrollment to improve trial success and patient outcomes.

Liver Awareness Month raises awareness of liver disease causes, risks, symptoms, and prevention, highlighting individual actions and policy efforts.

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

Elinzanetant offers a new hormone-free solution for managing menopause-related hot flashes, targeting the root cause of vasomotor symptoms.

Any injury to the eye, like those acquired during trick-or-treating, should be seen by an eye doctor if it does not resolve within a day.

Increases in global temperatures may exacerbate cardiovascular mortality risk in older patients with heart failure.

The trial evaluates ritlecitinib's efficacy for severe alopecia areata, utilizing innovative external placebo controls for enhanced patient outcomes.

Treating vasomotor symptoms, sleep disturbance, and mood disorders can remove barriers to weight loss for women during menopause, experts say.

This timeline highlights 5 key dates in September when the FDA approved treatments for cancers, dermatologic conditions, and rare diseases.

Discover how the SkinTracker app enhances AD management through remote assessments, offering convenience and accuracy comparable to in-person visits.

Questions remain related to which patients with diffuse large B-cell lymphoma (DLBCL) benefit most from radiotherapy and at what dose.

The FDA has approved belantamab mafodotin for third-line or later multiple myeloma based on DREAMM-7 trial data.

Removing out-of-pocket costs for follow-up colonoscopy led to an immediate and sustained increase in utilization.

AI-powered mammography is enhancing breast cancer screening and early detection through cutting-edge radiology insights.

Heart rate variability (HRV) biofeedback may be a potential intervention for patients with coronary artery disease.

Which hormonal contraceptives are still safe, when should women stop using them, and what other benefits do they offer during the menopause transition?

Using masks that tie up in the back and being aware of environmental factors can help protect eyes during Halloween trick-or-treating.

Explore the critical implications of proposed Medicaid cuts on health care access, costs, and community well-being in the US.

Can women feel relief from tinnitus and burning mouth syndrome during perimenopause and menopause?